Remarkably, cancers with EP300/CBP LOF showed higher neoantigen amount (Fig. 5F and SI Appendix, Fig. S8D), supporting the notion that tumor immunoediting shapes the neoantigen landscape (43, 44) and that EP300/CBP may be part of this process. This evidence concerns the gene EP300 and cancer.